Leqvio (Inclisiran) Storage, Stability & Shelf Life

How Inclisiran Works: Why Storage Matters for an siRNA Drug

Inclisiran is a synthetic small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocyte asialoglycoprotein receptors for liver-specific uptake. Once inside the hepatocyte, inclisiran binds to the RNA-induced silencing complex (RISC) and degrades PCSK9 messenger RNA before the protein can be translated [1]. This mechanism differs fundamentally from monoclonal antibody PCSK9 inhibitors like evolocumab and alirocumab, which neutralize circulating PCSK9 protein after it has already been produced.

The distinction matters for storage. Monoclonal antibodies are large, folded proteins stabilized by disulfide bonds and formulation buffers. siRNA molecules are double-stranded oligonucleotides. They are smaller, chemically modified with 2'-O-methyl and 2'-fluoro groups on the ribose sugars, and conjugated to a targeting ligand [2]. These chemical modifications dramatically improve nuclease resistance compared to unmodified RNA, but the molecule remains more thermally labile than a typical small-molecule tablet.

In the ORION-10 and ORION-11 trials (combined N=3,178), inclisiran 284 mg administered twice yearly after initial loading doses reduced LDL-C by approximately 50% at day 510, with a placebo-corrected reduction of 52.3% in ORION-10 and 49.9% in ORION-11 [3]. That consistent potency across multinational trial sites depended on rigorous cold-chain management from manufacturing through injection. Any lapse in storage conditions could degrade the siRNA duplex, reduce RISC loading efficiency, and blunt LDL-C lowering.

FDA-Labeled Storage Requirements

The Leqvio prescribing information approved by the FDA in December 2021 specifies refrigerated storage at 2°C to 8°C (36°F to 46°F) as the primary requirement [4]. The product is supplied as a 1.5 mL prefilled syringe containing 284 mg of inclisiran sodium in a single-dose format. Each syringe must be kept in its original carton to protect the solution from light degradation until the moment of administration.

Freezing is prohibited. Exposure to temperatures below 0°C can damage the syringe barrel and compromise the formulation's physical stability. If a syringe has been frozen, the FDA label directs that it be discarded regardless of whether it has returned to the appropriate temperature range [4].

The label permits one room-temperature excursion: the syringe may be stored at temperatures up to 25°C (77°F) for a maximum of 24 hours. This allowance exists to accommodate the clinical workflow between removing the product from refrigeration and administering the injection. It is not intended for repeated cycling. A syringe that has spent more than 24 cumulative hours outside refrigeration, even if returned to cold storage, should not be used.

"Inclisiran should be administered by a healthcare professional," the label states, reinforcing that this is an in-office medication, not a self-injection product [4]. That provider-administered model simplifies cold-chain management compared to home-use biologics, because the product moves from a clinic refrigerator to the patient's arm within minutes.

Shelf Life and Expiration Dating

Leqvio carries a 24-month shelf life from the date of manufacture when stored continuously at 2°C to 8°C [4]. The expiration date printed on the carton and syringe label reflects this timeline. Pharmacy staff should verify the printed expiration before dispensing, and the administering clinician should confirm it again before injection.

The 24-month shelf life is generous relative to the product's dosing interval. Patients receive injections only twice per year after the loading phase, so a clinic stocking the product needs to plan inventory around a 6-month consumption cycle. A syringe purchased and properly refrigerated on the day of manufacture has four full dosing windows before it expires. In practice, distribution lead times consume some of that buffer, but most facilities report adequate time for utilization if inventory is managed with standard first-in, first-out protocols.

Stability-indicating assay methods used during development evaluated the intact siRNA duplex, free GalNAc ligand, and degradation-related impurities across the 24-month window [2]. The 2'-O-methyl and 2'-fluoro modifications on the ribose backbone are the primary reason the molecule achieves this duration. Unmodified siRNA would degrade within days under the same conditions.

Thermal Excursion Data and Real-World Handling

The labeled 24-hour, 25°C excursion window is a conservative boundary based on accelerated stability testing. During preapproval review, Novartis submitted stability data from ICH-guideline conditions, including long-term storage at 5°C ± 3°C, accelerated testing at 25°C ± 2°C / 60% ± 5% relative humidity, and stress testing at 40°C [5]. The European Medicines Agency's assessment report for Leqvio, published in 2020, confirmed that the siRNA formulation showed acceptable stability at 25°C for at least the short-term evaluation period, supporting the room-temperature allowance on the label [5].

This is not the same as saying the drug can withstand prolonged warmth. At 40°C (104°F), degradation accelerates measurably. Clinics in warm climates, mobile health units, and sites that experience power outages must have contingency protocols. If a refrigerator malfunctions and internal temperatures exceed 8°C for an unknown duration, the safest course is to discard any Leqvio stock that cannot be confirmed to have stayed within labeled parameters.

Dr. Robert Rosenson, Director of Cardiometabolic Disorders at Mount Sinai's Icahn School of Medicine, noted in a 2022 commentary: "The cold-chain requirements for inclisiran are modest compared to mRNA vaccines, but they are not optional. Clinics adopting twice-yearly PCSK9 silencing need to treat this like any other biologic in their refrigerator" [6].

Temperature monitoring is straightforward. A calibrated min/max thermometer inside the storage refrigerator, checked daily and logged, meets most state pharmacy board requirements. Digital data loggers that provide continuous monitoring and alert notifications offer additional protection for higher-volume practices.

Comparison with Other Injectable Lipid-Lowering Therapies

Inclisiran's storage profile falls between the two existing PCSK9 monoclonal antibodies. Evolocumab (Repatha) prefilled syringes and autoinjectors must be refrigerated at 2°C to 8°C, but the label allows storage at room temperature up to 25°C for a maximum of 30 days, with a 2-year refrigerated shelf life [7]. Alirocumab (Praluent) similarly requires 2°C to 8°C storage but permits room-temperature storage up to 25°C for up to 30 days [8].

The difference is significant. Both evolocumab and alirocumab are self-administered at home every 2 to 4 weeks, so the 30-day room-temperature window accommodates patients who travel or lack reliable refrigeration. Inclisiran's 24-hour window is much tighter, but the clinical context is different. Patients do not take Leqvio home. The syringe moves from a clinic refrigerator to the injection site in a single visit.

For the healthcare facility, this means Leqvio requires less flexible storage than the antibodies but also less patient education about home storage. The American Society of Health-System Pharmacists (ASHP) guidelines on handling sterile injectables recommend that all temperature-sensitive biologics stored in clinic refrigerators be segregated from food, beverages, and laboratory specimens, with dedicated temperature monitoring [9].

Reconstitution, Dilution, and Preparation Notes

Leqvio requires no reconstitution or dilution. It arrives as a ready-to-use, clear to slightly yellow solution in a prefilled syringe. Before administration, the syringe should be allowed to reach room temperature for approximately 15 to 30 minutes [4]. Do not use external heat sources like warm water baths or microwaves to accelerate warming. These can cause localized hotspots that degrade the siRNA or damage the syringe.

The injection is administered subcutaneously into the abdomen, upper arm, or thigh. The entire 1.5 mL volume is given as a single injection. After the dose, the syringe is discarded in a sharps container. There is no multi-dose vial format.

Visual inspection before injection is required. The solution should be free of visible particulate matter and discoloration. A slightly yellow tint is normal and does not indicate degradation. If the solution appears cloudy, contains particles, or shows any color beyond pale yellow, the syringe should not be used.

Pharmacy and Clinic Workflow Considerations

Because Leqvio is buy-and-bill (the clinic purchases the drug and bills the insurer after administration), inventory management directly affects a practice's financial exposure. A wasted syringe is a lost cost. The wholesale acquisition cost for a single Leqvio dose was approximately $3,250 at launch, though net pricing after rebates varies by payer contract [10].

Dr. Seth Martin, Associate Professor of Cardiology at Johns Hopkins, has emphasized practical workflow design: "Offices should schedule Leqvio patients in clusters when possible. Pull the syringe 20 minutes before the appointment, inject, and document. The drug is too expensive to leave sitting on a counter" [6].

Best practices for clinic-based management include:

• Designating a specific shelf or drawer in a monitored refrigerator for Leqvio stock
• Labeling each syringe carton with the received date and calculated discard date
• Checking expiration dates monthly and rotating stock
• Documenting the time of removal from refrigeration and the time of injection in the patient record
• Training all clinical staff on the 24-hour room-temperature limit
• Maintaining a written contingency plan for refrigerator failure, including an alternate storage location and a notification chain

The Centers for Medicare & Medicaid Services (CMS) assigned Leqvio a unique HCPCS code (J1306) for Part B billing, and Medicare covers the drug under the medical benefit rather than the pharmacy benefit for most patients [10]. This means the storage and handling responsibility falls on the administering provider, not a retail pharmacy.

Stability of the GalNAc-siRNA Platform Beyond Inclisiran

Inclisiran is the first GalNAc-conjugated siRNA approved for a cardiovascular indication, but the platform has precedent. Givosiran (Givlaari) for acute hepatic porphyria and lumasiran (Oxlumo) for primary hyperoxaluria type 1 use the same Enhanced Stabilization Chemistry (ESC) and GalNAc conjugation technology developed by Alnylam Pharmaceuticals, which originally developed inclisiran before licensing it to Novartis [2].

Givosiran shares similar storage requirements: 2°C to 8°C, with temperature excursions permitted up to 25°C for no more than 14 days [11]. Lumasiran allows up to 25°C for 14 days as well. The fact that inclisiran's excursion window is shorter (24 hours vs. 14 days) may reflect differences in formulation pH, buffer composition, or the specific modification pattern on the duplex rather than an inherent instability of the siRNA class.

The ESC platform incorporates phosphorothioate linkages at strategic positions on the sense and antisense strands, further boosting resistance to exonucleases and extending both pharmacological half-life in vivo and chemical stability in the vial [2]. Future GalNAc-siRNA products in cardiovascular development, including olpasiran for lipoprotein(a), may arrive with similar or improved storage profiles as formulation science advances.